A new study published in Clinical Rheumatology exposes how vaccine manufacturers used phony placebos in clinical trials to conceal a wide range of devastating risks associated with HPV vaccines.
by Robert F. Kennedy Jr., guest author
Instead of using genuine inert placebos and comparing health impacts over a number of years, as is required for most new drug approvals, Merck and GlaxoSmithKline spiked their placebos with a neurotoxic aluminum adjuvant and cut observation periods to a matter of months.
Researchers from Mexico’s National Institute of Cardiology pored over 28 studies published through January 2017 — 16 randomized trials and 12 post-marketing case series — pertaining to the three human papillomavirus (HPV) vaccines currently on the market globally.
Read Entire Article »
by Robert F. Kennedy Jr., guest author
Instead of using genuine inert placebos and comparing health impacts over a number of years, as is required for most new drug approvals, Merck and GlaxoSmithKline spiked their placebos with a neurotoxic aluminum adjuvant and cut observation periods to a matter of months.
Researchers from Mexico’s National Institute of Cardiology pored over 28 studies published through January 2017 — 16 randomized trials and 12 post-marketing case series — pertaining to the three human papillomavirus (HPV) vaccines currently on the market globally.
Read Entire Article »
